Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 10.37% is 163% above its 5-year average of 3.94%, around the middle of its 5-year range (-18.81%–52.72%).
90.23% above its 12-month average of 5.45%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 14.08%.
GROSS MARGIN
10.37%
GROSS MARGIN AVG TTM
5.45%
GROSS MARGIN AVG 3Y
3.29%
GROSS MARGIN AVG 5Y
3.94%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+90.23%
CURRENT VS 3Y AVG
+214.93%
CURRENT VS 5Y AVG
+163.13%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
46.69%
median of 517 covered companies
CURRENT VS SECTOR MEDIAN
-77.79%
vs the sector median at left
Market Cap
$794.39M
Gross Margin
40.44%
TTM Avg
20.22%
3Y Avg
20.22%
5Y Avg
20.22%
Market Cap
$798.10M
Gross Margin
53.23%
TTM Avg
53.64%
3Y Avg
56.38%
5Y Avg
57.18%
Market Cap
$778.67M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$776.30M
Gross Margin
97.42%
TTM Avg
97.90%
3Y Avg
98.95%
5Y Avg
-3197.94%
Market Cap
$821.12M
Gross Margin
94.30%
TTM Avg
95.84%
3Y Avg
95.72%
5Y Avg
72.44%
Market Cap
$754.84M
Gross Margin
100.00%
TTM Avg
141.50%
3Y Avg
99.31%
5Y Avg
94.19%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AdaptHealth Corp. (AHCO) | $790.91M | 10.37% | 5.45% | 3.29% | 3.94% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $794.39M | 40.44% | 20.22% | 20.22% | 20.22% |
| Cytek Biosciences, Inc. (CTKB)vs › | $798.10M | 53.23% | 53.64% | 56.38% | 57.18% |
| Design Therapeutics, Inc. (DSGN)vs › | $778.67M | 0.00% | 0.00% | 0.00% | 0.00% |
| Geron Corporation (GERN)vs › | $776.30M | 97.42% | 97.90% | 98.95% | -3197.94% |
| InMode Ltd. (INMD)vs › | $814.22M | 76.52% | 79.43% | 81.57% | 82.72% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $821.12M | 94.30% | 95.84% | 95.72% | 72.44% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $754.84M | 100.00% | 141.50% | 99.31% | 94.19% |
| Ardelyx, Inc. (ARDX)vs › | $827.55M | 93.96% | 87.19% | 88.05% | 90.06% |
| Candel Therapeutics, Inc. (CADL)vs › | $749.92M | 0.00% | 0.00% | 25.00% | 50.00% |
Gross Margin
10.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 14.08% |
| 2026-04-10 | 12.37% |
| 2025-12-31 | 19.17% |
| 2025-09-30 | -9.25% |
| 2025-06-30 | -9.11% |
| 2025-03-31 | -13.26% |
| 2024-12-31 | 38.27% |
| 2024-09-30 | -14.11% |
| 2024-06-30 | -6.99% |
| 2024-03-31 | -6.89% |
| 2023-12-31 | 52.72% |
| 2023-09-30 | -18.81% |
| 2023-06-30 | -15.38% |
| 2023-03-31 | 11.98% |
| 2022-12-31 | 48.47% |
| 2022-09-30 | -15.97% |
| 2022-06-30 | -14.82% |
| 2022-03-31 | -13.83% |
| 2021-12-31 | 15.74% |
| 2021-09-30 | -12.08% |
| 2021-06-30 | 20.47% |
| 2021-03-31 | 17.72% |
| 2020-12-31 | 15.67% |
| 2020-09-30 | 15.36% |
| 2020-06-30 | 14.52% |
| 2020-03-31 | 12.44% |
| 2019-12-31 | 17.61% |
| 2019-09-30 | 18.57% |
| 2019-06-30 | 21.03% |
| 2019-03-31 | 18.23% |
| 2018-12-31 | 17.14% |
| 2018-09-30 | 17.49% |
| 2018-06-30 | 17.54% |
| 2018-03-31 | 17.54% |
